

Financial Results Briefing for the Fiscal Year Ended March 31, 2023

May 17, 2023 (WED)



©2023 TOHO HOLDINGS CO., LTD. All rights reserved



Agenda

- 1 Financial Highlights for the Fiscal Year Ended March 31, 2023
- 2 Forecast for Fiscal Year Ending March 31, 2024
- 3 Daizawa Project
- 4
- Medium-term Management Plan





Financial Highlights for the Fiscal Year Ended March 31, 2023



Financial Highlights for the Fiscal Year Ended March 31, 2023

(Unit: million Yen)

	FY ended Mai	rch 2022	FY ended March 2023				
	Sum	% of net sales	Sum	% of net sales	YoY change (%)		
Net sales	1,266,171		1,388,565		9.67		
Gross profit	108,687	8.58	110,814	7.98	1.96		
SG&A	96,159	7.59	98,000	7.06	1.91		
Operating profit	12,527	0.99	12,813	0.92	2.28		
Ordinary profit	18,182	1.44	19,176	1.38	5.47		
Net profit*	13,379	1.06	13,630	0.98	1.88		

*Profit attributable to owners of parent



Balance Sheet (Consolidated)

(Unit: million Yen)

	FY ended Ma	arch 2022	FY en	ded March	2023	Major factors behind
	Sum	Proportion (%)	Sum	Proportion (%)	Incr. or decr.	the increase or decrease
Current assets	513,107	73.05	533,519	74.59	20,412	Increase in accounts receivable-trade of 14,521 Increase in merchandise and finished goods of 11,048 Decrease in cash and deposits of 8,055
Non-current assets	189,268	26.95	181,768	25.41	-7,500	Decrease in property, plant and equipment of 4,382 Decrease in investments securities of 6,137
Total assets	702,376	100.00	715,288	100.00	12,912	
Current liabilities	402,819	57.35	440,188	61.54	37,369	Increase in accounts payable-trade of 15,128 Increase in current portion of bonds payable of 20,003
Non-current liabilities	58,275	8.30	32,183	4.50	-26,092	Decrease in bonds payable of 20,023 Decrease in long-term borrowings of 6,124
Total liabilities	461,095	65.65	472,372	66.04	11,277	
Net assets	241,281	34.35	242,916	33.96	1,635	Increase in retained earnings of 11,277 Increase in treasury shares of -7,388 Decrease in valuation difference on available-for-sale securities of 2,057
Total liabilities and net assets	702,376	100.00	715,288	100.00	12,912	
Equity-to-asset ratio FY end	ed March 2022: 34.	.30% FY ended	March 2023: 33.9	3%		



Profit and Loss Statement (Pharmaceutical Wholesaling Business)

• Sales and profit increased supported mainly by increases in sales of COVID-19-related products such as therapeutic drugs and testing kits due to the seventh and eighth waves of infections, and cancer drugs and specialty pharmaceuticals.

• The Company's net sales of limited-handling products for selected wholesalers were 167.8billion yen (16.5% increase from the previous period). *Excluding COVID-19-related products

• Customer support-related profit: 6.32 billion yen (Customer support systems: 3.75 billion yen, Meissa 2.57 billion yen)

(Unit: million Yen)

	FY ended Ma	rch 2022	FY ended March 2023			
	Sum	% of net sales	Sum	% of net sales	YoY change (%)	
Net sales	1,216,019		1,336,766		9.93	
Gross profit	73,735	6.06	74,911	5.60	1.59	
SG&A	63,767	5.24	64,468	4.82	1.10	
Operating profit	9,967	0.82	10,443	0.78	4.78	



Composition of Sales by Category and Contract Rate

Composition of sales by category

	April 2021-March 2022	April 2022-March 2023
Drugs for premium to promote the development of new drugs and eliminate off-label use	38.6%	41.5%
Patented drugs, others	32.7%	35.3%
Long-listed original drugs	15.7%	10.9%
Generic drugs	13.0%	12.2%

Contract rate

	2019/3	2020/3	2021/3	2022/3	2023/3
Value Basis	95.5%	99.7%	100.0%	100.0%	98.6%
Number Basis	86.7%	99.8%	100.0%	100.0%	100.0%



Profit and Loss Statement (Dispensing Pharmacy Business)

• We promoted responses to the revision of medical service fees and opened new pharmacies while closing existing ones with an emphasis on profitability.

• Declines in operating profit, affected by the revisions of NHI drug price and dispensing fees implemented in April 2022.

	FY ended Ma	arch 2022	FY ended March 2023			
	Sum	% of net sales	Sum	% of net Sales	YoY change (%)	
Net sales	91,801		92,346		0.59	
Gross profit	31,777	34.62	32,160	34.83	1.21	
SG&A	28,813	31.39	29,728	32.19	3.18	
Operating profit	2,963	3.23	2,431	2.63	-17.95	

■Number of stores (as of March 31, 2023)

	Consolidated Subsidiaries	Non-Consolidated Subsidiaries	Affiliates Companies	Total	
TOHO HOLDINGS	4 companies 77 stores	8 companies 53 stores	2 companies 16 stores	14 companies 146 stores	
PharmaCluster	6 companies 478 stores	10 companies 54 stores	2 companies 89 stores	18 companies 621 stores	
Total	10 companies 555 stores	18 companies 107 stores	4 companies 105 stores	32 companies 767 stores	



2 Forecast for Fiscal Year Ending March 31, 2024

Forecast for Fiscal Year Ending March 31, 2024(Consolidated)

×

From the fiscal year ending March 31, 2024, revenue from information service fees, which had previously been recorded as commission income of non-operating income, will be included in net sales. The change in presentation method is reflected in the consolidated forecast for that year. Therefore, the change in the presentation method is factored into the forecasts for the fiscal year ending March 31, 2024, whereas it is not factored into the results for the year ended March 31, 2023.

	FY ended Mai	rch 2023	FY ending March 2024 (Forecasts)					
	Sum	% of net	Fore	cast	ΥοΥ	change		
	Sum	sales	Sum	% of net sales	Incr. or Decr.	Incr. or Decr. (%)		
Net sales	1,388,565		1,325,000		_	-		
Gross profit	110,814	7.98	113,400	8.56	_	—		
SG&A	98,000	7.06	101,900	7.69	-	-		
Operating profit	12,813	0.92	11,500	0.87	_	-		
Ordinary profit	19,176	1.38	13,800	1.04	-	-		
Net profit *	13,630	0.98	12,300	0.93	-	-		

*Profit attributable to owners of parent

	FY ended Ma	rch 2023		FY ending March 2024 (Forecasts)				
	Sum	% of net	Fore	cast	Yo	Y change		
	Sum	sales	Sum	% of net sales	Incr. or Decr.	Incr. or Decr. (%)		
Net sales	1,391,857		1,325,000		-66,857	-4.80		
Gross profit	114,106	8.20	113,400	8.56	-706	-0.62		
SG&A	98,000	7.04	101,900	7.69	3,900	3.98		
Operating profit	16,105	1.16	11,500	0.87	-4,605	-28.59		
Ordinary profit	19,176	1.38	13,800	1.04	-5,376	-28.04		
Net profit *	13,630	0.98	12,300	0.93	-1,330	-9.76		

[Reference] Estimate results for the year ended March 31, 2023 if revenue from information service fees had been included in net sales.

Forecast for Fiscal Year Ending March 2024 (Pharmaceutical Wholesaling Business)



(Unit: million Yen)

	FY ended Mar	ch 2023	FY ending March 2024 (Forecasts)				
		% of net	Forec	ast	YoY change		
	Sum	sales	Sum	% of net sales	Incr. or Decr.	Incr. or Decr. (%)	
Net sales	1,336,766		1,273,000		_	_	
Gross profit	74,911	5.60	77,500	6.09	-	-	
SG&A	64,468	4.82	65,500	5.15	-	-	
Operating profit	10,443	0.78	12,000	0.94	-	-	

	FY ended Mar	ch 2023	FY ending March 2024 (Forecasts)				
		% of net	Forec	ast	YoY cl	hange	
	Sum	sales	Sum	% of net sales	Incr. or Decr.	Incr. or Decr. (%)	
Net sales	1,339,807		1,273,000		-66,807	-4.99	
Gross profit	77,952	5.82	77,500	6.09	-452	-0.58	
SG&A	64,468	4.81	65,500	5.15	1,032	1.60	
Operating profit	13,484	1.01	12,000	0.94	-1,484	-11.01	

[Reference] Estimate results for the year ended March 31, 2023 if revenue from information service fees had been included in net sales.

Forecast for Fiscal Year Ending March 2024 (Dispensing Pharmacy Business)



(Unit: million Yen)

	FY ended Mar	ended March 2023 FY ending March 2024 (Forecasts)				
	C	% of net	Forec	ast	ҮоҮ с	hange
	Sum	sales	Sum	% of net sales	Incr. or Decr.	Incr. or Decr. (%)
Net sales	92,346		92,400		-	_
Gross profit	32,160	34.83	32,100	34.74	-	-
SG&A	29,728	32.19	30,200	32.68	-	_
Operating profit	2,431	2.63	1,900	2.06	-	-

	FY ended Ma	arch 2023	F	Y ending March 202	24 (Forecasts)	
		% of net	Forecast		YoY change	
	Sum	% of net sales	Sum	% of net sales	Incr. or Decr.	Incr. or Decr. (%)
Net sales	92,352		92,400		48	0.05
Gross profit	32,166	34.83	32,100	34.74	-66	-0.21
SG&A	29,728	32.19	30,200	32.68	472	1.59
Operating profit	2,437	2.64	1,900	2.06	-537	-22.04

[Reference] Estimate results for the year ended March 31, 2023 if revenue from information service fees had been included in net sales.



Dividend Outlook


	Interim	Year End	Annual Dividend
FY ended March 2022	15yen	15yen	30yen
FY ended March 2023	16yen	16yen	32yen
FY ending March 2024 (Forecasts)	18yen (Ordinary dividend: 16yen Commemorative dividend: 2yen)	18yen (Ordinary dividend: 16yen Commemorative dividend: 2yen)	36yen (Ordinary dividend: 32yen Commemorative dividend: 4yen)

(*) We plan to pay an interim dividend of 18 yen per share and a year-end dividend of 18 yen per share for Fiscal year ending March 2024, with an annual dividend per share totaling 36 yen. Each of the interim and year-end dividends will be comprised of an ordinary dividend of 16 yen and a special dividend of 2 yen commemorating the 75th anniversary of the company's foundation.





Daizawa Project



After the relocation, the Head Office will continue to be located in Setagaya-ku, where the Company was founded, and will continue its community-based activities.

(4) Medium-term Management Plan 2023-2025 "Create the Next Generation"

Positioning of Medium-term Management Plan 2023-2025 "Create the Next Generation"

Our Mission

People who wish to be healthy	Solving issues to improve medical access	
Shareholders	Improvement of capital efficiency and enhancement of shareholder returns	2025
Customers	Providing value through quality control in pharmaceutical distribution and customer support	
Society	Protecting the environment through decarbonization actions and contributing to local communities through stable supply of pharmaceuticals	
Employees	Maximizing the value of human capital	

Medium-term Management Plan 2023-2025 "Create the Next Generation" -- "Create" the Foundation for the "Next Generation" --

2023

Basic policy and specific measures of the Medium-term Management Plan 2023-2025 "Create the Next Generation"

Business transformation

- Transformation of Pharmaceutical wholesaling business
- Transformation of Dispensing pharmacy business
- Regional development Regional healthcare design
- Cooperative Research Lab with AIST, MAXIS2021

Investment for growth and improvement of profitability

- Specialty products, Full service
- Improvement of customer support business
- Building new businesses

Alliance Further expansion of DX


Sustainability management

- Sustainability management of our company
- Maximize the value of human capital
- Compliance/ Risk management

Improvement of Capital Efficiency and Enhancement of Shareholder Returns

- · What the "next generation" should be like
- Specific measures under the Medium-term Management Plan 2023-2025 " Create the Next Generation"

[Business transformation] Transformation of Pharmaceutical wholesaling and Dispensing pharmacy business, and Regional development




[Business transformation] Cooperative Research Lab with AIST, MAXIS2021

Create the future together through open innovation **Implementation of Cooperative Research Lab with AIST** new technologies, **Kyoso Mirai group** AIST systems and Knowledge of the medical solve issues Advanced developm services in society industry capabilities related to access Know-how cultivated the Cutting-edge logistics functions, customer, to medical care technologies support systems and others **Create the** Period : April 1, 2023 to March 31, 2026 **Development** Next of human Generation **Create the future through Groupwide efforts** resources **MAXIS2021** Internal reform project "MAXIS2021" to ensure sustainable growth and remain a company that is needed by society Implementation of internal 3 reforms Internal Customer Sales Logistics Others operation support work

[Investment for growth and improvement of profitability] Specialty products, Full service

Able to meet the diverse needs of manufacturers (BPO (development / manufacturing outsourcing), etc.)

Establish a "Full service"




[Investment for growth and improvement of profitability] Improvement of customer support business




[Investment for growth and improvement of profitability] Building new businesses

We will build new businesses by proactively investing in areas and products related to medical care that are expected to grow.



[Sustainability management]

We will work to solve social issues through our business and contribute to the realization of a sustainable society.



What the "next generation" should be like

- **1.** Price Book-value Ratio (PBR)
- 2. Return On Equity (ROE)

3.

- : 1.0 times or higher (0.65 times in FY 2023)
- : More than 8% (5.6% in FY 2023)
- Dividend on Equity Ratio (DOE) : More than 2% (0.9% in FY 2023)

Specific measures under the Medium-term Management Plan 2023-2025

1) Investment Plan: 38 billion yen

- Investment in growth fields : 20 billion yen
- Investment in infrastructure : 12 billion yen
- Investment in human capital : 6 billion yen

2) Purchase of treasury shares : More than 30 billion yen

We will purchase treasury shares flexibly taking capital efficiency into consideration.

3) Dividends

We will increase dividends stably with a target of a DOE (dividend on equity) of 2%.

4) Cross-shareholdings

We will unwind cross-shareholdings in a phased manner through sufficient dialogue with the partner companies.



References

Cash Flow




	FY ended March 2022	FY ended March 2023	Major factors for FY ended March 2023
Cash and cash equivalents at the beginning of period	88,882	90,014	
Operating activities	16,341	-9	Profit before income taxes: 20,420 Increase in trade payables: -14,634 Increase in inventories: -10,854 Increase in trade payables: 14,685 Income taxes paid: -8,986
Investment activities	-11,032	4,315	Purchase of property, plant and equipment: -1,639 Proceeds from sale of property, plant and equipment: 1,807 Purchase of intangible assets: -880 Proceeds from sale of investment securities : 5,866
Financing activities	-4,473	-13,060	Proceeds from long-term borrowings: 3,610 Repayments of long-term borrowings: -6,395 Purchase of treasury shares: -7,390 Dividends paid: -2,187
Cash and cash equivalents at the end of period	90,014	81,839	Increase(FY ended March 2023): -8,175



SG&A (Year on Year)

<Year on Year>



FY ended March 2022 FY ended March 2023

×

Capital Investment and Depreciation

[Capital Investment]

FY ended March 2023	FY ending March 2024
Results: 3,309 million yen	Results: 6,791 million yen
 "TBC Hokuriku" (System, fixtures) 208 million yen Pharmaceutical sales office (New construction, relocation of sales office and others) : 892 million yen 	 Daizawa Project Move-in construction work · System · Furniture, fixtures, etc. : 970 million yen Pharmaceutical sales office (New construction, relocation of sales office and others) : 2,506 million yen
 3. Others : 2,209 million yen Including, replacement of core system servers : 633 million yen 	 3. Others : 3,315 million yen Including, replacement of core system servers : 474 million yen Distribution center WMS (warehouse management system) renovation, introduction of cloud-based systems, etc. : 923 million yen
[Depreciation]	

FY ended March 2023	FY ending March 2024
5,767 million yen	6,139 million yen



Total commitment to good health



[Front office in charge of IR] Corporate Communications and Investor Relations E-mail: info@so.tohoyk.co.jp https://www.tohohd.co.jp

[Notice]

Statements contained in this presentation that are not past facts are forward-looking statements that reflect our plans, expectations, strategies and assumptions, and involve known and unknown risks and uncertainties. These statements are based on currently available information and represent the beliefs of the management of TOHO HOLDINGS CO., LTD. These statements are subject to numerous risks and uncertainties that could cause actual results, performance and achievements to differ materially from those described or implied in the forward-looking statements. Since many factors could cause the actual results to differ substantially from these forward-looking statements, investors are advised to avoid undue reliance on the latter. This presentation has not been prepared for the purpose of stimulating investment. Any decision to invest is the sole responsibility of the individual investor. In addition, the information about the pharmaceutical products included in the document is not a thing aimed for advertising and medical advice.